Severance Hospital
Seoul, Seodaemun-gu, 120-752, South Korea
NCT Number: NCT02156544
The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519.
Looking for future studies?
Notify Me19 year–55 year
All sexes
Interventional
Phase 1
Seoul, Seodaemun-gu, 120-752, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 0(predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168
Time frame: 0(Predose), 0.5, 1, 2, 4, 8, 18, 24, 48, 72, 96, 120, 144, 168
Chong Kun Dang Pharmaceutical
Industry
A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers
Acronym: CKD-519 FIH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT07691268
Dyslipidemia, Dyslipidemias
Seoul, Gwanak-gu 08779, South Korea
View Trial DetailsNCT07627555
Cardiovascular Diseases, Dyslipidemia
Lahore, Pakistan
View Trial DetailsNCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial Details